Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Rank in Stocks #93
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and... Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Share Price
$137.21
Market Cap
$170.34B
Change (1 day)
-2.76%
Change (1 year)
28.14%
Country
US
Trade Gilead Sciences, Inc. (GILD)

Category

Revenue for Gilead Sciences, Inc. (GILD)
Revenue in Dec 2025 TTM: $29.44B
According to Gilead Sciences, Inc. latest financial reports the company's current revenue (TTM) is $29.44B. In 2024 the company made a revenue of $28.75B an increase over the revenue in the year 2023 that was $27.12B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Gilead Sciences, Inc. from 2000 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $29.44B 0.00%
2025 $29.44B 2.40%
2024 $28.75B 6.04%
2023 $27.12B -0.60%
2022 $27.28B -0.09%
2021 $27.31B 10.60%
2020 $24.69B 9.98%
2019 $22.45B 1.46%
2018 $22.13B -15.24%
2017 $26.11B -14.09%
2016 $30.39B -6.89%
2015 $32.64B 31.13%
2014 $24.89B 122.19%
2013 $11.20B 15.46%
2012 $9.70B 15.70%
2011 $8.39B 5.48%
2010 $7.95B 13.38%
2009 $7.01B 31.40%
2008 $5.34B 26.14%
2007 $4.23B 39.78%
2006 $3.03B 49.19%
2005 $2.03B 53.13%
2004 $1.32B 52.63%
2003 $867.86M 85.92%
2002 $466.79M 99.68%
2001 $233.77M 19.54%
2000 $195.56M 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$65.18B 121.38%
US
$58.74B 99.51%
GB
$94.19B 219.93%
US
$61.16B 107.73%
US
$56.15B 90.71%
CH